Citi lowered the firm’s price target on Evolent Health (EVH) to $33 from $35 and keeps a Buy rating on the shares as part of a Q3 earnings preview. The firm thinks Evolent shares have “been unfairly punished” by what it views as idiosyncratic Medicaid headwinds that largely haven’t impacted the company’s two most significant Medicaid clients.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EVH: